Blechacz B, Komuta M, Roskams T, et al. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2011;8:512–22. https://doi.org/10.1038/nrgastro.2011.131.

Article  PubMed  PubMed Central  Google Scholar 

Valle JW, Kelley RK, Nervi B, et al. Biliary tract cancer. Lancet. 2021;397:428–44. https://doi.org/10.1016/S0140-6736(21)00153-7.

Article  CAS  PubMed  Google Scholar 

Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8–10. https://doi.org/10.1200/JCO.1995.13.1.8.

Article  CAS  PubMed  Google Scholar 

Lievens Y, Guckenberger M, Gomez D, et al. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiother Oncol. 2020;148:157–66. https://doi.org/10.1016/j.radonc.2020.04.003.

Article  PubMed  Google Scholar 

Kroese TE, van Laarhoven HWM, Nilsson M, et al. Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: A systematic review and meta-analysis. Eur J Cancer. 2022;166:254–69. https://doi.org/10.1016/j.ejca.2022.02.018.

Article  CAS  PubMed  Google Scholar 

Iyengar P, All S, Berry MF, et al. Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline. Pract Radiat Oncol. 2023;13:393–412. https://doi.org/10.1016/j.prro.2023.04.004.

Article  PubMed  Google Scholar 

Kang JI, Sufficool DC, Hsueh CT, et al. A phase I trial of Proton stereotactic body radiation therapy for liver metastases. J Gastrointest Oncol. 2019;10:112–7. https://doi.org/10.21037/jgo.2018.08.17.

Article  PubMed  PubMed Central  Google Scholar 

Hua YQ, Wang P, Zhu XY, et al. Radiofrequency ablation for hepatic oligometastatic pancreatic cancer: An analysis of safety and efficacy. Pancreatology. 2017;17:967–73. https://doi.org/10.1016/j.pan.2017.08.072.

Article  PubMed  Google Scholar 

Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393:2051–8. https://doi.org/10.1016/S0140-6736(18)32487-5.

Article  PubMed  Google Scholar 

Niibe Y, Hayakawa K. Oligometastases and oligo-recurrence: The new era of cancer therapy. Jpn J Clin Oncol. 2010;40:107–11. https://doi.org/10.1093/jjco/hyp167.

Article  PubMed  PubMed Central  Google Scholar 

Peixoto RD, Renouf D, Lim H. A population based analysis of prognostic factors in advanced biliary tract cancer. J Gastrointest Oncol. 2014;5:428–32. https://doi.org/10.3978/j.issn.2078-6891.2014.081.

Article  PubMed  PubMed Central  Google Scholar 

Okamoto T, Takeda T, Sasaki T, et al. Safety and Effectiveness of Chemotherapy in Elderly Biliary Tract Cancer Patients. Curr Oncol. 2023;30:7229–40. https://doi.org/10.3390/curroncol30080524.

Article  PubMed  PubMed Central  Google Scholar 

Franzese C, Bonu ML, Comito T, et al. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity. J Cancer Res Clin Oncol. 2020;146:2289–97. https://doi.org/10.1007/s00432-020-03285-9.

Article  PubMed  Google Scholar 

Kojima T, Umeda Y, Fuji T, et al. Efficacy of surgical management for recurrent intrahepatic cholangiocarcinoma: A multi-institutional study by the Okayama Study Group of HBP surgery. PLoS ONE. 2020;15:e0238392. https://doi.org/10.1371/journal.pone.0238392.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Buettner S, Ten Cate DWG, Bagante F, et al. Survival after Resection of Multiple Tumor Foci of Intrahepatic Cholangiocarcinoma. J Gastrointest Surg. 2019;23:2239–46. https://doi.org/10.1007/s11605-019-04184-2.

Article  PubMed  PubMed Central  Google Scholar 

Kudo M, Han KH, Ye SL, et al. A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. Liver Cancer. 2020;9:245–60. https://doi.org/10.1159/000507370.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gaito S, Marvaso G, Ortiz R, et al. Proton Beam Therapy in the Oligometastatic/Oligorecurrent Setting: Is There a Role? A Literature Review. Cancers (Basel). 2023;15:2489. https://doi.org/10.3390/cancers15092489.

Article  PubMed  Google Scholar 

House MG, Ito H, Gönen M, et al. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg. 2010;210:744–55. https://doi.org/10.1016/j.jamcollsurg.2009.12.040.

Article  PubMed  Google Scholar 

Imaoka H, Mizuno N, Hara K, et al. Evaluation of modified glasgow prognostic score for pancreatic cancer: A retrospective cohort study. Pancreas. 2016;45:211–7. https://doi.org/10.1097/MPA.0000000000000446.

Article  PubMed  Google Scholar 

Tang H, Lu W, Li B, et al. Prognostic significance of neutrophil-to-lymphocyte ratio in biliary tract cancers: a systematic review and meta-analysis. Oncotarget. 2017;8:36857–68. https://doi.org/10.18632/oncotarget.16143.

Article  PubMed  PubMed Central  Google Scholar 

Takeda T, Sasaki T, Okamoto T, et al. Outcomes of pancreatic cancer with liver oligometastasis. J Hepatobiliary Pancreat Sci. 2023;30:229–39. https://doi.org/10.1002/jhbp.1184.

Article  PubMed  Google Scholar 

Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47. https://doi.org/10.1016/j.ejca.2008.10.026.

Article  CAS  PubMed  Google Scholar 

National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v.5.0. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Accessed November 23, 2023

Morino K, Seo S, Yoh T, et al. Proposed Definition for Oligometastatic Recurrence in Biliary Tract Cancer Based on Results of Locoregional Treatment: A Propensity-Score-Stratified Analysis. Ann Surg Oncol. 2020;27:1908–17. https://doi.org/10.1245/s10434-020-08207-0.

Article  PubMed  Google Scholar 

Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240:644–58. https://doi.org/10.1097/01.sla.0000141198.92114.f6.

Article  PubMed  PubMed Central  Google Scholar 

Yoshida K, Yamaguchi K, Okumura N, et al. Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer. 2016;19:329–38. https://doi.org/10.1007/s10120-015-0575-z.

Article  PubMed  Google Scholar 

Furuse J, Shibahara J, Sugiyama M. Development of chemotherapy and significance of conversion surgery after chemotherapy in unresectable pancreatic cancer. J Hepatobiliary Pancreat Sci. 2018;25:261–8. https://doi.org/10.1002/jhbp.547.

Article  PubMed  Google Scholar 

Hu LS, Zhang XF, Weiss M, et al. Recurrence Patterns and Timing Courses Following Curative-Intent Resection for Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2019;26:2549–57. https://doi.org/10.1245/s10434-019-07353-4.

Article  PubMed  Google Scholar 

Miwa S, Miyagawa S, Kobayashi A, et al. Predictive factors for intrahepatic cholangiocarcinoma recurrence in the liver following surgery. J Gastroenterol. 2006;41:893–900. https://doi.org/10.1007/s00535-006-1877-z.

Article  CAS  PubMed  Google Scholar 

Kato A, Shimizu H, Ohtsuka M, et al. Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: a retrospective single-center study. Ann Surg Oncol. 2013;20:318–24. https://doi.org/10.1245/s10434-012-2312-8.

Article  PubMed